Separately, breast cancers with a combined negative expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2), which has therapeutic implications, are classified as triple-negative breast cancer (TNBC) [7]. This evidence concerns the gene PGR and breast carcinoma.